SILEXION THERAPEUTICS CORP Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
SILEXION THERAPEUTICS CORP (SLXN) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $90.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- SILEXION THERAPEUTICS CORP increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $90.00K.
- SILEXION THERAPEUTICS CORP increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$60.00K.
- SILEXION THERAPEUTICS CORP increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $143.00K.
- SILEXION THERAPEUTICS CORP increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $88.00K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $90.00K 10-Q · filed 2026-08-14 | $30.00K 10-Q · filed 2026-08-14 | $173.00K derived: sum of 3 quarters · filed 2026-08-14 | $261.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$60.00K S-1/A · filed 2026-08-10 | $83.00K derived: sum of 2 quarters · filed 2026-08-10 | $171.00K derived: sum of 3 quarters · filed 2026-08-10 | $132.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $143.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $231.00K derived: sum of 2 quarters · filed 2026-08-10 | $192.00K derived: sum of 3 quarters · filed 2026-08-14 | $102.00K S-1/A · filed 2026-08-10 |
| 2025-09-30 | $88.00K 10-Q · filed 2025-11-12 | $49.00K derived: sum of 2 quarters · filed 2026-08-14 | -$41.00K 10-Q · filed 2025-11-12 | -$1.06M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$39.00K 10-Q · filed 2026-08-14 | -$129.00K 10-Q · filed 2026-08-14 | -$1.14M derived: sum of 3 quarters · filed 2026-08-14 | -$2.05M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$90.00K S-1/A · filed 2026-08-10 | -$1.10M derived: sum of 2 quarters · filed 2026-08-10 | -$2.01M derived: sum of 3 quarters · filed 2026-08-10 | -$1.68M derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | -$1.01M derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | -$1.92M derived: sum of 2 quarters · filed 2026-08-10 | -$1.59M derived: sum of 3 quarters · filed 2026-08-10 | -$1.90M S-1/A · filed 2026-08-10 |
| 2024-09-30 | -$905.00K 10-Q · filed 2025-11-12 | -$578.00K derived: sum of 2 quarters · filed 2025-11-12 | -$884.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $327.00K 10-Q · filed 2025-08-12 | $21.00K 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |